Biological treatments in allergy: prescribing patterns and management of hypersensitivity reactions
- Barakat, Leyla
- Torres, Maria Jose
- Phillips, Elizabeth
- Caminati, Marco
- Chang, Yoon-Seok
- Caimmi, Davide
- Sanchez-Borges, Mario
- Rosenwasser, Lanny
- Didier, Alain
- de Blay, Frédéric
- Fontaine, Jean-François
- Bosse, Isabelle
- Lefevre, Sebastien
- Bassani, Cintia
- de Filippo, Maria
- Asontegui, Igancio
- Morais-Almeida, Mario
- Ebisawa, Motohiro
- Martin, Bryan
- Thong, Bernard Yu-Hor
- Demoly, Pascal
- Tanno, Luciana Kase
DOIAbstract
International audienceBiological agents (BA) are emerging as potential effectivetreatment for allergic and hypersensitivity disorders (A/H). Fourmain classes of BA are now (May 2020) approved by US Foodand Drug Administration and European Medicines Agency forA/H: anti-IgE (omalizumab),1 anti-IL5 (mepolizumab, reslizu-mab),2 anti-IL4/13 (dupilumab),3 and anti-IL5R (benralizu-mab).4 Hypersensitivity reactions (HSR) due to BA can occurwith different severity degrees, which hamper their use. Newtypes of HSR have been reported with lack of standardized andguided allergy worku
Add to ORKG